ライフサイエンスコーパス: leukemogenic

1 d differentiation in vivo in TM and were not leukemogenic.

2 tion appear to support the notion that it is leukemogenic.

3 ntrast, HTLV-2, which expresses Tax2, is non-leukemogenic.

4 ETO in hematopoietic cells is not by itself leukemogenic.

5 at CD105(+) blasts are endowed with superior leukemogenic activity compared with the CD105(-) populat

6 epressor recruitment by ETO and clues to the leukemogenic activity of AML1-ETO.

7 iferation, clonogenic potential, and in vivo leukemogenic activity of BCR/ABL-expressing myeloid 32Dc

8 The effectors mediating the leukemogenic activity of CDX2 and the mechanism underlyi

9 The leukemogenic activity of MLL fusion proteins is dependen

10 sential oncogenic co-factor required for the leukemogenic activity of MLL fusion proteins.

11 Disruption of this pathway abrogates the leukemogenic activity of MLL fusions.

12 m in a lineage-dependent manner, showing the leukemogenic activity of MLL-Af4 was interlinked with ly

13 rthenolide (PTL) can impair the survival and leukemogenic activity of primary human acute myeloid leu

14 protein stabilization may contribute to the leukemogenic activity of the fusion protein.

15 focus-forming (MCF) viruses and the enhanced leukemogenic activity of the latter, we tested XMRV for

16 vitro transformation properties, and in vivo leukemogenic activity of the P190, P210, and P230 forms

17 naling to Abl interactor proteins affect its leukemogenic activity.

18 suggesting the three proteins have different leukemogenic activity.

19 mology domain of Runx2 are essential for its leukemogenic activity.

20 Dosing per cycle and cumulative dosing of leukemogenic agents peaked with N6, which included four

21 idence that alkylating agents, certain other leukemogenic agents, and total-body irradiation (TBI) ca

22 alfold higher than that of the LTR of weakly leukemogenic Akv virus.

23 ETO family proteins and the leukemogenic AML1-ETO fusion protein are corepressors of

24 Both viruses were less leukemogenic and had a longer mean latency period than M

25 is expressed by this translocation is poorly leukemogenic and requires additional mutations for trans

26 of high-dose chemotherapy might be minimally leukemogenic, and (2) it contrasts strikingly with the p

27 controls hematopoiesis, its dysregulation is leukemogenic, and its influence on GATA factor function

28 constitutive v-Rel expression appears to be leukemogenic at earlier stages of T-cell development.

29 This combination can be potently leukemogenic, but the particular manner in which these t

30 a factor-dependent cell line FDC.P1 was made leukemogenic by transfection with the human BCR/ABL gene

31 n in response to THPO in vitro and increased leukemogenic capacity in vivo.

32 tem cells) may be particularly vulnerable to leukemogenic changes induced by carcinogens.

33 To understand the leukemogenic chromatin signature, we analyzed acute prom

34 This study reveals that the leukemogenic CM fusion protein disrupts adult erythropoi

35 With the leukemogenic concerns of viral gene therapy there is a n

36 nses and the mechanisms of the hemotoxic and leukemogenic consequences of radiation exposure.

37 f the FLT3 and PIM1 genes, another important leukemogenic driver.

38 may contribute an essential function to the leukemogenic effect of DEK-CAN and SET-CAN.

39 Thus, the leukemogenic effect of MN1-TEL in our knock-in mice is p

40 hat BHLHB1, similar to SCL/TAL1, may exert a leukemogenic effect through a functional inactivation of

41 that MN1-TEL exerts its nonlineage-specific leukemogenic effects by promoting the growth of primitiv

42 susceptibility of myeloid stem cells to the leukemogenic effects of etoposide have not been elucidat

43 These results suggest that the leukemogenic effects of HRX fusion proteins may be relat

44 The molecular basis for the leukemogenic effects of these fusion proteins is incompl

45 with topoisomerase-II inhibitors is strongly leukemogenic, even with modest cumulative doses of each

46 f the GATA1 mutation suggests it is an early leukemogenic event.

47 Cooperating leukemogenic events in MLL-rearranged (MLL-r) infant acu

48 ogenic levels of Notch1 can complement other leukemogenic events, such as activation of K-ras.

49 naling induces Meis1, recapitulating several leukemogenic features of Hoxa9/Meis1-driven leukemia.

50 roperty appears to be specific to exogenous, leukemogenic FeLVs.

51 ls expressing PKC412-sensitive or -resistant leukemogenic FLT3 mutants.

52 ntaining HOX gene dysregulation as a driving leukemogenic force.

53 oproteolytic domain, frequently missing from leukemogenic forms of the protein, in complex with the N

54 n the myeloid compartment, and modulates the leukemogenic function of Cbfbeta-SMMHC in mouse leukemia

55 L-AF6 fusion gene represents the most common leukemogenic fusion of mixed lineage leukemia (MLL) to a

56 MOZ-TIF2 is a leukemogenic fusion oncoprotein that confers self-renewa

57 the MLL repression domain is retained in the leukemogenic fusion protein and is required for transfor

58 The resulting leukemogenic fusion proteins are transcriptional repress

59 d with an inability to target the removal of leukemogenic fusion proteins, aberrant epigenetic regula

60 Here we show that 3 leukemogenic fusion proteins, BCR-ABL, CBFB-MYH11, and R

61 atic RUNX1 alteration was found in AMLs with leukemogenic fusion proteins, such as core-binding facto

62 human cord blood cells and those expressing leukemogenic fusion proteins, we discovered a dual role

63 c malignancies are typically associated with leukemogenic fusion proteins, which are required to main

64 ation by an MLL fusion protein but not other leukemogenic fusion proteins.

65 promising therapeutic strategy for AMLs with leukemogenic fusion proteins.

66 As many genes involved in leukemogenic fusions play a role in normal hematopoiesis

67 MLL fusion proteins that bind DNA and drive leukemogenic gene expression.

68 H3K79 methylation and aberrant expression of leukemogenic genes.

69 r with E47, to activate aberrantly a set of "leukemogenic" genes in T cells.

70 o smoke exposure influences the formation of leukemogenic genomic deletions.

71 The leukemogenic GMP displayed higher levels of beta-catenin

72 ncy may have contributed to the formation of leukemogenic GMP, restoration of E2A-function did not re

73 ress only non-DNA binding dominant-negative "leukemogenic" Ikaros isoforms lacking critical N-termina

74 genes in human acute leukemias and is highly leukemogenic in experimental models.

75 Whether this gene, which is leukemogenic in mice, also plays a leukemogenic role in

76 Conversely, enforced HOXA9 expression is leukemogenic in mice, and HOXA9 is frequently activated

77 iferation and survival, has been shown to be leukemogenic in mice, is detected in LSCs of more than 5

78 R/ABL-BaF3 cells, a murine cell line that is leukemogenic in mice, SCH66336 potently inhibited soft a

79 3 and NHR4 domains of AML1-ETO and is highly leukemogenic in the mouse model.

80 one marrow failure and that loss of Trp53 is leukemogenic in this model.

81 th acute lymphoblastic leukemia (ALL) can be leukemogenic in vivo when expressed in normal hematopoie

82 sed levels of the shorter, dominant negative leukemogenic isoform (p30) of CCAAT enhancer-binding pro

83 arness, rather than inhibit, the activity of leukemogenic kinases to kill transformed cells, this app

84 Here we report that the leukemogenic kinases, Bcr-Abl, FLT3/D835Y, and Tel-PDGFR

85 n accessibility at putative enhancers of key leukemogenic loci.

86 emic disease and indicates a cell autonomous leukemogenic mechanism.

87 In this article, leukemogenic mechanisms have been identified in a number

88 leukemia (CML) and may help elucidate basic leukemogenic mechanisms in CML stem cells during disease

89 scovery of novel, therapeutically targetable leukemogenic mechanisms.

90 or down-regulating high endogenous levels of leukemogenic microRNAs by antisense oligonucleotides (an

91 7-W) of the murine leukemia virus MCF 247, a leukemogenic mink cell focus-inducing (MCF) virus, the U

92 n1 excision also suppresses proliferation of leukemogenic mixed lineage leukemia-AF9 fusion-protein-t

93 A subgroup of leukemogenic mixed-lineage leukemia (MLL) fusion protein

94 When transduced with a leukemogenic MLL fusion gene, prospectively isolated ste

95 A leukemogenic MLL fusion protein that activates Hox expre

96 Leukemogenic MLL fusion proteins cause overexpression of

97 Leukemogenic MLL fusion proteins delete the MLL SET doma

98 ed the MLL CXXC domain in the context of the leukemogenic MLL-AF9 fusion with CXXC domains from DNMT1

99 om stem cells or conferred on progenitors by leukemogenic molecules remains unknown.

100 cells are sustained in distinct fractions by leukemogenic mutations.

101 studies show that (1) mice vaccinated with a leukemogenic number of AML cells engineered to express B

102 These leukemogenic NUP98 fusion proteins interacted with CRM1,

103 y was undertaken to determine the effects of leukemogenic NUP98 fusion proteins on CRM1-mediated nucl

104 d in response to some oncogenes, such as the leukemogenic oncogene BCR-ABL, which is created by a rec

105 hat is transformed into a significantly more leukemogenic oncoprotein.

106 that result in defective splicing are a new leukemogenic pathway.

107 ever, BCR-ABL-independent factors, including leukemogenic pathways involving kinases other than BCR-A

108 nd the development of new agents targeted to leukemogenic pathways promise to further improve outcome

109 of E2A-corepressor interactions in distinct leukemogenic pathways.

110 Induction of the leukemogenic phenotype is generally associated with inap

111 terleukin 3 dependence and produced a highly leukemogenic phenotype.

112 vertheless abrogated during progression to a leukemogenic phenotype.

113 hout undergoing apoptosis and retained their leukemogenic phenotype.

114 ociated with a facilitated diminution of the leukemogenic PML-RARalpha protein and retained DeltaPML-

115 lentiviral vectors can effectively alter the leukemogenic potency when the degree of suppression of e

116 apoptotic program where translocations with leukemogenic potential are created within cells that hav

117 f activating c-KIT mutations differ in their leukemogenic potential in association with RUNX1-ETO, we

118 dent cell cycle progression, and rescued the leukemogenic potential in mice.

119 liferation of these cells, but reduced their leukemogenic potential in vivo, possibly by recruitment

120 tivity of Bcr-Abl/p210 was essential for its leukemogenic potential in vivo.

121 ematopoietic cells but is essential for full leukemogenic potential in vivo.

122 The leukemogenic potential is cause for concern and preclude

123 n a more physiological system, we tested the leukemogenic potential of a clone of K562 cells (K6 K562

124 In this study, we compared the leukemogenic potential of activated NRAS, KRAS, and HRAS

125 I1 oncogenic components are required for the leukemogenic potential of AME and for the cooperation of

126 for determining which factors compromise the leukemogenic potential of AML1-ETO.

127 The leukemogenic potential of BCR/ABL oncoproteins depends o

128 of some RNA binding proteins suppresses the leukemogenic potential of BCR/ABL-expressing cells.

129 e of Vav by viral proteins may relate to the leukemogenic potential of certain HTLV-I-infected cells.

130 kemia (AML, n = 81), and directly tested the leukemogenic potential of constitutive expression of SAL

131 In parallel, we studied the in vivo leukemogenic potential of dominant negative (DN) and tru

132 In this study, we evaluated the leukemogenic potential of EVI1-, MDS1/EVI1- and AML1-rel

133 hematopoiesis and demonstrate the conserved leukemogenic potential of human IDH1 mutations in zebraf

134 to increase the risk of transformation, the leukemogenic potential of hydroxyurea (HU) continues to

135 role in APL pathogenesis by facilitating the leukemogenic potential of PML-RARalpha.

136 isease background may be a crucial factor in leukemogenic potential of retroviral gene therapy and un

137 Here, we assessed the leukemogenic potential of SET-CAN in the hematopoietic s

138 cription and ultimately the cell tropism and leukemogenic potential of the virus.

139 th factor-independent proliferation, and the leukemogenic potential of these cells.

140 To define the leukemogenic potential of V72M NE, a tumor watch was est

141 ions, and outline putative mechanisms of its leukemogenic potential.

142 range of chimeric transcription factors with leukemogenic potential.

143 rest and apoptosis prior to fulfilling their leukemogenic potential.

144 cells expressing only p185DeltaBCR showed no leukemogenic potential.

145 leukemia (AML) activated AMPK and maintained leukemogenic potential.

146 osine kinase that possesses sarcomagenic and leukemogenic potential.

147 nus have been shown to have greatly enhanced leukemogenic potential.

148 reduced THPO-induced JAK/STAT signaling and leukemogenic potential.

149 for BCR/ABL clonogenic activity and in vivo leukemogenic potential.

150 cytokine receptor common gamma-chain yields leukemogenic pre-B cells that exhibit greater sensitivit

151 Our findings provide insights into the leukemogenic process and may be clinically important in

152 on, and for the use of in vivo models of the leukemogenic process in preclinical or diagnostic studie

153 haracterize the role of the ALL1 gene in the leukemogenic process, and possibly in solid malignancies

154 leukemias and MDS and may play a role in the leukemogenic process.

155 egulated Notch target gene activation in the leukemogenic process.

156 ruption of TNTs significantly inhibits these leukemogenic processes and resensitizes B-cell precursor

157 PML-RARalpha protein, the leukemogenic product of t(15,17) in acute promyelocytic

158 the PI3K-AKT pathway as key elements of the leukemogenic program activated by NOTCH1 and provide the

159 hancer plays a causal role in the onset of a leukemogenic program.

160 LSCs depend on not only active expression of leukemogenic programs, but also DNA methylation-mediated

161 acute promyelocytic leukemia (APL) carrying leukemogenic promyelocytic leukemia-retinoic acid recept

162 These results show that Tel-Abl has leukemogenic properties from distinct from those of Bcr-

163 In addition, the leukemogenic properties of BCR/ABL in a murine model sys

164 ooperating events that may contribute to its leukemogenic properties, are discussed.

165 ) translocation and target PML-RARalpha, the leukemogenic protein, by different pathways suggesting a

166 ing domain transforms AML1-ETO into a potent leukemogenic protein.

167 more than one signaling pathway required by leukemogenic PTKs may improve the treatment of primary a

168 Thus, we reveal an entirely novel type of leukemogenic Ras signals that is based on a RasGRP1-driv

169 ation of a histone methyltransferase and its leukemogenic rearrangement that regulates expression of

170 vidence that this constitutive activation is leukemogenic renders this receptor a potential target fo

171 which is leukemogenic in mice, also plays a leukemogenic role in humans will require further study.

172 mic p27 induces apoptosis, consistent with a leukemogenic role of cytoplasmic p27.

173 Therefore, the current study shows a leukemogenic scenario of human ALL in which programs of

174 g-receptor editing and after germinal-center leukemogenic selection.

175 pregulation of HGF expression in maintaining leukemogenic signaling by this receptor.

176 otch1 in T-cell progenitors and suggest that leukemogenic signaling involves recruitment of transcrip

177 the FTK protein network and transduction of leukemogenic signaling.

178 SRS 19-6 MuLV genome contribute to its broad leukemogenic spectrum.

179 induce myeloid leukemias, yet have distinct leukemogenic strengths and phenotypes.

180 lex, a master regulator of hematopoiesis and leukemogenic target.

181 id malignancy (secondary AML [s-AML]), after leukemogenic therapy (therapy-related AML [t-AML]), or w

182 c treatment for neuroblastoma or to truncate leukemogenic therapy, eg, by exploiting molecular techni

183 enous leukemia stems from events invoked for leukemogenic topo II cleavable complex-stabilizing antit

184 r CBP, as well as core components of a major leukemogenic transcriptional complex that contains RUNX1

185 + cells, unlike HSCs, are more accessible to leukemogenic transformation after the loss of p18.

186 Point mutations within IBM2 abolished leukemogenic transformation by MLL-AF9, validating that

187 Fas may act as a tumor suppressor to control leukemogenic transformation in myeloid progenitor cells.

188 is a hematopoietic disorder initiated by the leukemogenic transformation of myeloid cells into leukem

189 ns and Kras G12D contribute cooperatively to leukemogenic transformation of normal T-cells.

190 ivated Akt and growth-factor independence in leukemogenic transformation, and demonstrate the potenti

191 or epigenetic defects are necessary for full leukemogenic transformation.

192 e chimeric fusion protein resulting from the leukemogenic translocation t(17;19), appears to employ e

193 the spleen and bone marrow and was part of a leukemogenic translocation, its role in hematopoiesis ha

194 r failed decatenation, it is surprising that leukemogenic translocations do not occur more frequently

195 yielded new insights into the mechanisms of leukemogenic translocations.

196 Efforts to devise effective but less leukemogenic treatment for neuroblastoma or to truncate

197 ation for apoptosome inhibition by activated leukemogenic tyrosine kinases and suggest that alteratio

198 rse leukemia cell lines expressing different leukemogenic tyrosine kinases, including BCR-ABL and FMS

199 P2/p27 conduit may be a universal target for leukemogenic tyrosine kinases.

200 The retrovirus type B leukemogenic virus (TBLV) causes T-cell lymphomas in mic

201 Type B leukemogenic virus (TBLV) induces rapidly appearing T-ce

202 Type B leukemogenic virus (TBLV) induces rapidly appearing T-ce

203 Type B leukemogenic virus (TBLV) is a variant of mouse mammary

204 Type B leukemogenic virus (TBLV) is highly related to mouse mam

205 Type B leukemogenic virus (TBLV), a mouse mammary tumor virus (

206 Type B leukemogenic virus is a variant of mouse mammary tumor v

207 85 delta BCR/Bcl-2 double transfectants were leukemogenic when injected into immunodeficient mice, bu

208 riant of M-MuLV, Mo+PyF101 M-MuLV, is poorly leukemogenic when used to inoculate mice s.c., but not w

209 p185DeltaBCR/M-Raf double transfectants were leukemogenic, whereas cells expressing only p185DeltaBCR